DATA GRAPHICS | Data Byte
The evolving geographic atrophy pipeline
Roche drops galegenimab and NGM data disappoint, as regulatory milestones approach for Apellis, Iveric
October 19, 2022 12:28 AM UTC
A flurry of geographic atrophy news this year has seen the clinical pipeline evolve, while revealing that not all complement inhibitors are similarly effective.
As the two leaders in the field, both with complement-targeting programs, continue to advance, this week has seen anti-C3 mAb NGM621 from NGM Biopharmaceuticals Inc. (NASDAQ:NGM) fail to meet its primary endpoint in a Phase II trial, as well as a decision by Roche (SIX:ROG; OTCQX:RHHBY) to discontinue development of anti-HTRA1 mAb galegenimab (RG6147)...